(firstQuint)Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe.

 PURPOSE is a randomized double-blind placebo-controlled study.

 Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis.

 The primary outcome measure is the rate of transition to psychosis as determined through CAARMS.

 Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo.

 This study in conducted at 18 sites in 9 countries.

.

 Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe@highlight

The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.

